乙酰唑胺对缺血性卒中的治疗效果:一项Meta分析与系统综述
该研究检索7个数据库至2023年4月,纳入5项缺血动物模型研究,评估乙酰唑胺疗效。结果显示乙酰唑胺可减轻发病24小时脑水肿并抑制水通道蛋白-4表达,但对神经功能改善作用不确定。
要点
- 乙酰唑胺减轻缺血动物模型发病24小时脑水肿,标准化均数差-2.00(95%CI -3.57至-0.43,P=0.01)。
- 乙酰唑胺抑制发病24小时水通道蛋白-4表达,标准化均数差-1.46(95%CI -2.01至-0.91,P<0.001)。
- 乙酰唑胺对缺血动物神经功能的作用因研究数据有限而不确定。
核心结论
- 乙酰唑胺在缺血性卒中早期抑制水通道蛋白-4并减轻脑水肿,但似乎不能改善神经功能。
研究设计与样本
- 系统综述与Meta分析,检索Embase、Cochrane Library、PubMed、Web of Science、中国知网、万方数据库和中国生物医学文献数据库至2023年4月,纳入缺血动物模型研究。
- 共筛选376篇文章,最终纳入5项研究。
- 采用实验性卒中动物数据Meta分析与综述协作方法评估动物试验质量。
主要发现
- 乙酰唑胺减轻脑缺血发病24小时脑水肿,标准化均数差-2.00(95%CI -3.57至-0.43,P=0.01)。
- 乙酰唑胺抑制发病24小时水通道蛋白-4表达,标准化均数差-1.46(95%CI -2.01至-0.91,P<0.001)。
- 发病第3天脑水肿和水通道蛋白-4表达也呈下降趋势,但数据不足支持。
- 乙酰唑胺对动物脑缺血神经功能的作用因研究数据有限而不确定。
局限性
- 仅纳入5项研究。
- 发病第3天脑水肿和水通道蛋白-4表达的下降趋势数据不足支持。
- 乙酰唑胺对神经功能的作用因研究数据有限而不确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ischemic stroke significantly contributes to high mortality and disability rates. Cerebral edema is a common consequence of ischemic stroke and can lead to aggravation or even death. Current treatment strategies are limited to decompressive craniectomy and the intravascular administration of hypertonic drugs, which have significant side effects. Acetazolamide (ACZ) plays a therapeutic role in cerebral edema by inhibiting aquaporin-4 (AQP-4) and improving collateral circulation. This study aimed to perform a meta-analysis and systematic review of ACZ therapy for ischemic stroke and evaluate its efficacy in animal models. METHODS: We searched Embase, Cochrane Library, PubMed, Web of Science, Chinese National Knowledge Infrastructure, Wanfang Database, and Chinese Biomedical Literature Database until April 2023 for studies on ACZ in ischemic animal models. The quality of the animal trials was assessed using the Collaborative Approach to Meta-Analysis and Review of Animal Data from Experimental Stroke. RESULTS: After screening 376 articles, only 5 studies were included. We found that ACZ reduced brain edema in cerebral ischemia 24 hours after onset (standard mean difference, -2.00; 95% confidence interval, -3.57 to -0.43, P = 0.01). ACZ also inhibited AQP-4 expression 24 hours after onset (standard mean difference-1.46; 95% confidence interval, -2.01 to -0.91, P < 0.001). Brain edema and AQP-4 expression also showed a declining trend on the third day after onset, although there were not enough data to support this. The effect of ACZ on brain ischemia in animals' neurological function is uncertain because of the limited research data. CONCLUSIONS: ACZ inhibited AQP-4 and alleviated brain edema after ischemic stroke in the early stages but seemingly could not improve the neurological function.
引用
- Liu M, Li H, Fan L, et al. Treatment Effects of Acetazolamide on Ischemic Stroke: A Meta-Analysis and Systematic Review. World Neurosurg. 2024. PMID: 38423457. doi:10.1016/j.wneu.2024.02.123
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。